<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="2436">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 16, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05129449</url>
  </required_header>
  <id_info>
    <org_study_id>2018-GI (OEKG) - 01 Phase B</org_study_id>
    <nct_id>NCT05129449</nct_id>
  </id_info>
  <brief_title>A Clinical Study With the Medical Device PowerSpiral for Endoscopic Retrograde Cholangio-Pancreatography (ERCP)</brief_title>
  <acronym>SAMISEN-B</acronym>
  <official_title>Safety and Performance of the Motorized Spiral Endoscope PowerSpiral in Subjects Indicated for Small-bowel Enteroscopy or Endoscopic Retrograde Cholangio-Pancreatography (ERCP) in Subjects With Surgically Altered Gastrointestinal Anatomy.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Olympus Europe SE &amp; Co. KG</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Olympus Europe SE &amp; Co. KG</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of the SAMISEN study phase B is to assess the performance and safety of&#xD;
      diagnostic and therapeutic procedures with the Olympus Motorized Spiral Enteroscope&#xD;
      (PowerSpiral) in subjects with surgically altered gastrointestinal anatomy indicated for an&#xD;
      Endoscopic Retrograde Cholangio-Pancreatography (ERCP).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The main objective of this registry is to collect data on the safety and performance of the&#xD;
      motorized PowerSpiral device during Post-market Clinical Follow-up in subjects with&#xD;
      surgically altered gastrointestinal anatomy indicated for an Endoscopic Retrograde&#xD;
      Cholangio-Pancreatography (ERCP). It is assumed that this motorized PowerSpiral device and&#xD;
      its safety profile is non-inferior to preceding generations of balloon assisted enteroscopes.&#xD;
&#xD;
      As clinical performance and efficacy is equally important for the user this study also&#xD;
      collects efficacy and handling data of the motorized PowerSpiral device.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">November 30, 2021</start_date>
  <completion_date type="Anticipated">May 30, 2023</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Total success rate</measure>
    <time_frame>up to 12 days</time_frame>
    <description>Defined as the combined percentage of Enteroscopy success rate, Biliary Cannulation success rate and Procedural (Therapeutic) success rate.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Total procedure time</measure>
    <time_frame>up to 12 days</time_frame>
    <description>starting with oral insertion until final withdrawal of the device</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Enteroscopy time</measure>
    <time_frame>up to 12 days</time_frame>
    <description>starting with oral insertion until reaching the papilla or the biliary anastomosis</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Collect Serious Adverse Events and Device Deficiencies to demonstrate safety of the Motorized Spiral Endoscope (PowerSpiral) in daily medical practice.</measure>
    <time_frame>up to 12 days</time_frame>
    <description>Incidence (% of subjects) and frequency (no. of subjects) with Serious Adverse Events (SAEs) and Device Deficiencies (DD) which meet the severity grading of moderate or severe for the following categories:&#xD;
Enteroscopy-associated complications (mainly bleeding and perforation(s))&#xD;
ERCP-related complications (Dumonceau et al. 2020)&#xD;
Sedation / anesthesia related complications&#xD;
other</description>
  </primary_outcome>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Cholangiopancreatography, Endoscopic Retrograde</condition>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Endoscopic Retrograde Cholangio-Pancreatography (ERCP)</intervention_name>
    <description>Endoscopic Retrograde Cholangio-Pancreatography (ERCP) conducted with motorized PowerSpiral in subjects presenting with surgically altered GI anatomy indicated for ERCP with biliary indication.</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Subjects presenting with surgically altered GI anatomy indicated for ERCP with biliary&#xD;
        indication, which fulfil all inclusion and none of the exclusion criteria.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion criteria&#xD;
&#xD;
          1. Signed informed consent&#xD;
&#xD;
          2. Patients with surgically altered upper Gastrointestinal anatomy (Roux-en-Y and&#xD;
             Billroth II types) with a biliary indication for ERCP where access with conventional&#xD;
             ERCP devices is of no avail and after careful risk assessment.&#xD;
&#xD;
        Exclusion criteria In addition to be eligible for study enrollment a subject must not meet&#xD;
        any of the exclusion criteria listed below.&#xD;
&#xD;
          1. Age under 18 years&#xD;
&#xD;
          2. Female and of child-bearing age who is currently pregnant or planning to become&#xD;
             pregnant within the study period&#xD;
&#xD;
          3. Any contraindication to standard enteroscopy or ERCP (e.g. severe coagulopathy or&#xD;
             known coagulation disorder; bowel obstruction / stenosis, stents or other instruments&#xD;
             implanted in the intestinal tract, suspected GI perforation, esophageal or gastric&#xD;
             varices, eosinophilic esophagitis) as judged by the investigator after careful&#xD;
             individual risk assessment&#xD;
&#xD;
          4. Concurrent participation in another competing clinical study&#xD;
&#xD;
          5. Pancreatic indication for ERCP in patient with surgically altered anatomy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Torsten Beyna, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Evangelisches Kranken-haus Düssel-dorf</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Tom G. Moreels, Prof.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cliniques universitaires Saint-Luc</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Peter Teichmann, PhD</last_name>
    <phone>+49 40 23773-0</phone>
    <phone_ext>-7835</phone_ext>
    <email>Peter.Teichmann@Olympus.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hôpital Erasme</name>
      <address>
        <city>Brussels</city>
        <country>Belgium</country>
      </address>
    </facility>
    <contact>
      <last_name>NA NA</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Cliniques universitaires Saint-Luc</name>
      <address>
        <city>Bruxelles</city>
        <country>Belgium</country>
      </address>
    </facility>
    <contact>
      <last_name>Tom G. Moreels, Prof.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Evangelisches Krankenhaus Düsseldorf</name>
      <address>
        <city>Duesseldorf</city>
        <country>Germany</country>
      </address>
    </facility>
    <contact>
      <last_name>Torsten Beyna, MD PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospital Frankfurt a.M.</name>
      <address>
        <city>Frankfurt</city>
        <country>Germany</country>
      </address>
    </facility>
    <contact>
      <last_name>NA NA</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>OUS-Rikshospitalet University Hospital</name>
      <address>
        <city>Oslo</city>
        <country>Norway</country>
      </address>
    </facility>
    <contact>
      <last_name>NA NA</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Germany</country>
    <country>Norway</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>November 10, 2021</study_first_submitted>
  <study_first_submitted_qc>November 10, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">November 22, 2021</study_first_posted>
  <last_update_submitted>November 10, 2021</last_update_submitted>
  <last_update_submitted_qc>November 10, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 22, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

